4.7 Article

Nattokinase mitigated dextran sulfate sodium-induced chronic colitis by regulating microbiota and suppressing tryptophan metabolism via inhibiting IDO-1

Journal

JOURNAL OF FUNCTIONAL FOODS
Volume 75, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.jff.2020.104251

Keywords

Nattokinase (NK); Chronic colitis; Gut microbiota; Tryptophan metabolism; Indoleamine 2; 3-dioxygenase 1 (IDO-1)

Funding

  1. National Natural Science Foundation of China [81703556]
  2. Natural Science Foundation of Jiangsu Province [BK20171024]
  3. Jiangsu Provincial key research and development program [BE2019737]
  4. Nanjing International Science and Technology Cooperation Program [201911015]
  5. Jiangsu Synergetic Innovation Center for Advanced Bio-Manufacture [XTD1819]
  6. National Key Special Project of Science and Technology for Innovation Drugs of China [2017ZX09301-013]

Ask authors/readers for more resources

In this study, we investigated the protective effect of Nattokinase (NK), the most active ingredient in natto used for healthcare, on dextran sulfate sodium (DSS)-induced chronic colitis and unraveled the potential mechanisms. NK dramatically attenuated clinical symptoms and pathological damage of DSS-induced chronic colitis. NK also inhibited proinflammatory cytokines production in DSS-induced colonic tissues. Mucosal integrity was maintained by NK. Moreover, nattokinase reversed DSS-induced decline of bacteria community diversity and intestinal microbial imbalance by decreasing levels of Firmicutes and increasing levels of Bacteroidetes. Tryptophan (Trp) metabolism analysis demonstrated that NK suppressed Trp catabolism especially the Kynurenine (Kyn) pathway in chronic colitis. Furthermore, NK strikingly down-regulated the protein expression of IDO-1 in chronic colitis mice. Taken together, the study demonstrated that NK relieved DSS-induced chronic colitis by regulating gut microbiota and suppressing Trp metabolism via inhibiting IDO-1. This study indicated that NK might be a promising and effective agent for IBD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available